Back
PYCAI
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PYCAI
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in PYCAI
N/A
PYCAI investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in PYCAI also invest in...
Want more shares? Try these...
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technologies based on cell penetrating peptides (CPPs) and peptide conjugated phosphorodiamidate morpholino oligomer (PPMOs). The firm develops a pipeline of therapies, including two programs, which are focused on inherited eye diseases and preclinical discovery programs, which are focused on neurodegenerative and kidney diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate PYC-001, which is focused on treating autosomal dominant optic atrophy (ADOA). Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
📊 Share price